Applied Genetic Tech Q1 EPS $(0.40) Misses $(0.35) Estimate

Applied Genetic Tech (NASDAQ:AGTC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 33.33 percent increase over losses of $(0.60) per share

byBenzinga Newsdesk

November 9, 2021

1 minute read

JP Morgan Downgrades Cyteir Therapeutics to Neutral

By Benzinga Newsdesk

Today, 5:31 AM

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

CYT

Jasper Therapeutics Presented Updated Data from Phase 1 Clinical Trial of JSP191

By Ragothaman Srinivasan

Today, 5:31 AM

Jasper Therapeutics, Inc., (NASDAQ: JSPR) announced updated efficacy, safety and pharmacokinetic data from its Phase 1 clinical trial of JSP191, in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.

JSPR

Needham Initiates Coverage On Intra-Cellular Therapies with Buy Rating, Announces Price Target of $55

By Benzinga Newsdesk

Today, 5:31 AM

Needham analyst Ami Fadia initiates coverage on Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy rating and announces Price Target of $55.

ITCI

CORRECTION: Tower Semiconductor Q3 EPS $0.41 Beats $0.37 Estimate, Sales $387.00M Beat $384.97M Estimate

By Benzinga Newsdesk

Today, 5:31 AM

Tower Semiconductor (NASDAQ:TSEM) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.37 by 10.81 percent. This is a 127.78 percent increase over earnings of $0.18 per share

TSEM

Applied Genetic Tech Q1 EPS $(0.40) Misses $(0.35) Estimate

Related Posts

JP Morgan Downgrades Cyteir Therapeutics to Neutral

Jasper Therapeutics Presented Updated Data from Phase 1 Clinical Trial of JSP191

Needham Initiates Coverage On Intra-Cellular Therapies with Buy Rating, Announces Price Target of $55

CORRECTION: Tower Semiconductor Q3 EPS $0.41 Beats $0.37 Estimate, Sales $387.00M Beat $384.97M Estimate